Rekombinanter SARS-CoV-2 Spike S1 Antikörper (RBD)

Produktnummer ABIN6952547

Dieses Rabbit Chimeric-Antikörper erkennt spezifisch SARS-CoV-2 Spike S1 in ELISA, IF, Crys, SPR. Er zeigt eine Reaktivität gegenüber SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV), SARS CoV-2 Alpha, SARS CoV-2 Beta, SARS CoV-2 Epsilon, SARS CoV-2 Gamma, SARS CoV-2 Eta, SARS CoV-2 Kappa und wurde in 5+ Publikationen erwähnt.

Kurzübersicht für Rekombinanter SARS-CoV-2 Spike S1 Antikörper (RBD) (ABIN6952547)

Target: SARS-CoV-2 Spike S1

Antikörpertyp: Recombinant Antibody

Reaktivität: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV), SARS CoV-2 Alpha, SARS CoV-2 Beta, SARS CoV-2 Epsilon, SARS CoV-2 Gamma, SARS CoV-2 Eta, SARS CoV-2 Kappa

Wirt: Kaninchen

Klonalität: Chimeric

Konjugat: Dieser SARS-CoV-2 Spike S1 Antikörper ist unkonjugiert

Applikation: ELISA, Immunofluorescence (IF), Crystallization (Crys), Surface Plasmon Resonance (SPR)

Klon: CR3022

Produktdetails anti-SARS-CoV-2 Spike S1 Antikörper

Highlights:

• Recombinant human neutralizing antibody (hNAb) against SARS-CoV-2.
• Binds SARS-CoV-2 S proteins of lineages B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.429 (epsilon), and B.1.525 (eta).
• Frequently used as reference in S-protein ELISAs and neutralization assays.
• Synergizes with other hNAbs: binds a highly conserved epitope.
• No interference with the ACE2 binding site.

Bindungsspezifität: RBD

Verwendungszweck: Recombinant monoclonal antibody to COVID-19 & SARS-CoV S glycoprotein.

Spezifität:

The chimeric SARS-CoV S1 antibody (CR3022) binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318-510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein (Joyce et al. 2020).

While most S-protein RBD binding antibodies compete for antigen binding with ACE2, the CR3022 epitope does not overlap with the ACE2-binding site. It does thus not hinder binding of neutralizing antibodies. While CR3022 on its own exhibits only a weak neutralizing effect, it has been shown to synergize with other S-protein RBD binding antibodies to neutralize SARS-CoV. This effect still has to be confirmed in context with SARS-CoV-2 (Yuan et al. 2020).

Kreuzreaktivität (Details): The anti-SARS-CoV-2 antibody (CR3022) was originally discovered in a SARS patient, but it was shown to be a potent binder of SARS-CoV-2 spike protein (S1).

Produktmerkmale:

Original Species of Ab: Human

Original Format of Ab: IgG1

Aufreinigung: Protein A affinity purified

Immunogen: The original monoclonal antibody was generated through an scFv library derived from a peripheral blood lymphocytes of a patient exposed to the SARS-CoV.

Isotyp: IgG kappa

Anwendungsinformationen

Applikationshinweise: This antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 < a href="https://www.medrxiv.org/content/10.1101/2020.03.17.20037713v1" target="_blank">(Amanat et al. 2020). Human IgG2 and IgG4 subtypes, which are also seen in a small subset of COVID-19 patients, are also available to investigate their role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-ompeting SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020). Bates et al. 2021 (PMID: 32766589) used CR3022 in a immunofluorescence assay.

Kommentare:

This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Referenzen für anti-SARS-CoV-2 Spike S1 Antikörper (ABIN6952547)

Xing, Dorey, Jayasinghe, Howorka: "Highly shape- and size-tunable membrane nanopores made with DNA." in: Nature nanotechnology, (2022) (PubMed).

Tian, Li, Huang, Xia, Lu, Shi, Lu, Jiang, Yang, Wu, Ying: "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody." in: Emerging microbes & infections, Vol. 9, Issue 1, pp. 382-385, (2020) (PubMed).

Stadlbauer, Amanat, Chromikova, Jiang, Strohmeier, Arunkumar, Tan, Bhavsar, Capuano, Kirkpatrick, Meade, Brito, Teo, McMahon, Simon, Krammer: "SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup." in: Current protocols in microbiology, Vol. 57, Issue 1, pp. e100, (2020) (PubMed).

Yuan, Wu, Zhu, Lee, So, Lv, Mok, Wilson: "A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV." in: Science (New York, N.Y.), (2020) (PubMed).

ter Meulen, van den Brink, Poon, Marissen, Leung, Cox, Cheung, Bakker, Bogaards, van Deventer, Preiser, Doerr, Chow, de Kruif, Peiris, Goudsmit: "Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants." in: PLoS medicine, Vol. 3, Issue 7, pp. e237, (2007) (PubMed).

Details zu SARS-CoV-2 Spike S1

Target: SARS-CoV-2 Spike S1

Substanzklasse: Viral Protein

Hintergrund: Spike protein, COVID19, COVID 19, S protein, SARS-CoV S protein, S glycoprotein, E2, Peplomer protein, Spike protein S1, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV, Ab1680.10, Ab1680.15, Ab1680.16

UniProt: P59594